PubMed Health⌕ Search

Biomedical subjects

L Tomio

Publications and source records attributed to L Tomio.

At least 37 records · Page 2Linked to original sources
PubMed1990

Oesophageal cancer treated by photodynamic therapy alone or followed by radiation therapy.

Photodynamic therapy (PDT) with porphyrins and red light is receiving increasing attention in the management of malignant tumours. At present PDT is primarily indicated for the treatment of superficial or early-stage lesions. At the Department of Radiotherapy and the First Institute of Surgery in Padova (Italy) more than 150 cases of tumours of different types have been treated using this technique. This paper briefly describes 21 cases of superficial oesophageal cancer. A complete response was observed in 11 of 21 cases. Radiation therapy appeared to be very effective as a salvage treatment of non-response patients.

Antineoplastic Agents↗
PubMed1987

[Laser-photo-radiotherapy in the treatment malignant tumors].

Photoradiation therapy or, as more recently defined, photodynamic therapy (PDT) has been effective in the treatment of several kinds of cancers, above all of the skin, lung, esophagus and bladder. It is based on the preferential retention by tumor and photosensitizing properties of certain porphyrins. We began to investigate this technique experimentally in 1978 and clinically in september 1982, with report of the initial results in 38 patients in 1985. In this paper we describe our more recent experience of PDT in 18 patients affected by different tumors and treated with a new double argon-dye laser system. These tumors included 8 carcinomas of the esophagus, 5 basal cell skin cancers, 2 carcinomas of the lung, 2 squamous cell carcinomas of the oral cavity and 1 early gastric cancer. Clinical results and technical problems of PDT are discussed.

Hematoporphyrin Photoradiation↗
PubMed1987

[Natural history of cancer of the breast. Probability of developing bone metastases].

The incidence of bone metastases in 448 patients with breast cancer was evaluated. 374 out of 448 cases showed negative bone scan at initial clinical staging and were followed up during a period of at least 5 years with serial bone scans. The results of bone scans were compared on the basis of clinical stage (according to the International UICC classification), of lymph node involvement (groups N0, N + ) and of complementary therapy after surgery (radiotherapy v/s hormone-chemotherapy). Cumulative probability of bone metastases in breast cancer showed a linear trend with annual mean rate of 5% (1st yr 2%; 2nd yr 8%; 3rd yr 15%; 4th yr 22%; 5th yr 29%; 10th yr 59%). Statistical analysis in different clinical stages showed mild difference not statistically significant, neither in lymph node involvement (NO v/s N + ) nor in complementary therapy (radiotherapy v/s hormone-chemotherapy).

Bone Neoplasms↗
PubMed1986

Controlled targeting of different subcellular sites by porphyrins in tumour-bearing mice.

Unilamellar liposomes of dipalmitoyl-phosphatidylcholine can incorporate various porphyrins in either the phospholipid bilayer or the internal aqueous compartment depending on the water-/lipo-solubility of the drug. Intraperitoneal injection of the liposome-bound porphyrins to mice bearing a MS-2 fibrosarcoma results in remarkably more efficient tumour targeting than that obtained by administration of the same porphyrins dissolved in homogeneous aqueous solution. Moreover, also water-insoluble porphyrins can be transported to the tumour via liposomes. Fractionation of liver and neoplastic cells indicates that the subcellular distribution of liposome-delivered porphyrins is also dependent on their solubility properties: thus, relatively polar porphyrins, such as tetra(4-sulfonatophenyl)porphine and uroporphyrin, are mainly recovered from the soluble fraction, whereas hydrophobic porphyrins, such as haematoporphyrin or porphyrin esters, preferentially partition in the cytoplasmic membrane. As a consequence, different subcellular sites can be targeted by porphyrins and possibly photodamaged through a suitable choice of the drug-carrier system.

Animals↗
PubMed1984

Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo.

Hematoporphyrin (5 mg/ml), administered intravenously to tumor-bearing patients, becomes associated with different serum proteins, including lipoproteins (mainly HDL), globulin and albumin. No residual porphyrin is bound to the two latter classes of proteins after 48 h, whereas the complexation with the lipoproteins appears to be particularly stable probably owing to the hydrophobic nature of hematoporphyrin. The late persistence of hematoporphyrin in serum is due to the binding to the VLDL fraction with special regard to its cholesterol moiety. The importance of hematoporphyrin transport by lipoproteins for the photodynamic therapy of tumors is briefly discussed.

Blood Proteins↗